severe fever with thrombocytopenia syndrome
Conditions
Interventions
M group:Oral molnupiravir 800 mg q12h for 5 days
Control group:Oral placebo, four capsules q12h for 5 days
Sponsors
Juxian People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Subjects must meet all of the following enrollment criteria to be enrolled in this study: 1. Age =18 years at the time of signing the informed consent. 2. Meet the diagnostic criteria for confirmed cases in the Guidelines for the Prevention and Treatment of Fever with Thrombocytopenia Syndrome (2010 edition). 3. Understand and comply with the study procedures and methods, voluntarily participate in this trial, and sign the informed consent in writing.
Exclusion criteria
Exclusion criteria: Subjects with any of the following are not eligible for enrollment in this study: 1. A prior history of molnupiravir allergy; 2.Application of other antiviral drugs including ribavirin and favipiravir. 3. Women who are pregnant, planning to become pregnant or breastfeeding, or who have a positive blood/urine pregnancy test result at the time of screening 4. Those who, as determined by the study physician, are likely to be alive for less than 24 hours at screening; 5. Any physical or psychological disease or condition that, as determined by the study physician, is likely to increase the risk of the trial, affect the subject's compliance with the protocol, or interfere with the subject's ability to complete the trial. 6.Participated in a clinical trail of drug within 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 28-day all-cause mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of ICU admissions;Number of days from admission to negative virus tests;Days of hospitalization;Changes in laboratory indicators; | — |
Countries
China
Contacts
Public ContactYongyuan Yao
Juxian People's Hospital
Outcome results
None listed